ALBOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (3 3月 2023 @ 06:00):

Stats
本日の出来高	1.24M
平均出来高	566 901
時価総額	915.89M
EPS	$0 ( 2023-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.63
ATR14	$0.932 (2.11%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-02	Chiswell David	Sell	56 278	Common Stock
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	5 500	Stock Option (Right to Buy)

INSIDER POWER
-49.92
Last 100 transactions
Buy: 1 059 000 \| Sell: 2 762 067

ボリューム相関

長: 0.36 (neutral)

短: 0.10 (neutral)

Signal:(68.034) Neutral

Albireo Pharma Inc 相関

10 最も正の相関
WPRT	0.988
APTO	0.982
RESN	0.98
RXDX	0.977
RETA	0.972
MTEM	0.969
CSII	0.965
IMGN	0.963
VREX	0.963
ZGNX	0.962

10 最も負の相関
AAON	-0.975
EYE	-0.975
THRX	-0.969
IEP	-0.962
APLS	-0.96
PEBK	-0.956
PINC	-0.956
VRAR	-0.952
BRQS	-0.95
NVCT	-0.948

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Albireo Pharma Inc 相関 - 通貨/商品

0.07
( neutral )

0.68
( moderate )

0.56
( weak )

0.35
( neutral )

0.59
( weak )

-0.03
( neutral )

Albireo Pharma Inc 財務諸表

Annual	2021
収益:	$40.58M
総利益:	$39.22M (96.66 %)
EPS:	$-1.770

FY	2021
収益:	$40.58M
総利益:	$39.22M (96.66 %)
EPS:	$-1.770

FY	2020
収益:	$8.31M
総利益:	$0.00 (0.00 %)
EPS:	$-6.73

FY	2019
収益:	$9.64M
総利益:	$0.00 (0.00 %)
EPS:	$-5.04

Financial Reports:

No articles found.

Albireo Pharma Inc

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.